Global Oncology Academy

Best Practices for Existing Epidermal Growth Factor Receptor (EGFR) Inhibitor Agents

    The management of metastatic colorectal cancer (mCRC) and metastatic and recurrent loco-regional squamous cell cancer of the head and neck (SCCHN) ...
    • Overview

      The management of metastatic colorectal cancer (mCRC) and metastatic and recurrent loco-regional squamous cell cancer of the head and neck (SCCHN) continues to evolve, not only as new agents reach the clinic but also new understandings of how best to utilize existing agents to optimize clinical outcomes for patients. One of the continuing areas of focus is use of inhibitors of the epidermal growth factor receptor (EGFR) pathway. For both mCRC and metastatic and recurrent loco-regional SCCHN, increasing attention is being placed on second-line approaches as well as first-line application in combination with radiation therapy and/or platinum-based chemotherapy.

    Facebook Comments

    NEW FEATURES: